Trial intelligence / Profile preview

Subcutaneous Dermatophagoides pteronyssinus extract for local allergic rhinitis

2008-003680-39Phase 2Active

Sponsor: Servicio de Alergia. Hospital Civil. MÃ¡laga (Spain)
Start: Apr 2009
Modality: Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Countries: 1

Overview

Phase 2, randomised, double-blind trial in allergic rhinitis (AR) comparing Pangramin Plus with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Apr 2009; status: active.

Drugs

dermatophagoides pteronyssinus extract

Conditions

allergic rhinitis (AR)

Beyond the preview

Go deeper on 2008-003680-39.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-003680-39.